Genmab scores hat-trick with positive late-stage trial results

Jefferies analysts note Genmab reported positive results for petosemtamab in metastatic head and neck cancer, opening a $3.5B sales opportunity. Another $3.5B potential in locally advanced disease. Shares fell 2.6% but up 43% for the week. Detailed response rate data awaited.